A Phase 2 interventional study of Acalabrutinib (Arm A) and Acalabrutinib (Arm B) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 25th largest by enrollment, is one of 4 that started in 2015, is one of 22 in phase 2, and was the 2nd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 19th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 10th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have relapsed/refractory disease or treatment naive deletion 17p.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active disease as defined by at least one of the following (IWCLL consensus criteria):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
Drug: Acalabrutinib (Arm A) · Drug: Acalabrutinib (Arm B)
Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
Drug: Acalabrutinib (Arm A) · Drug: Acalabrutinib (Arm B)
* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W; * A1b) acalabrutinib, dose A daily: biopsy (T) schedule V. * A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y; * A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z
Also known as: ACP-196
B1c) acalabrutinib, dose A daily: biopsy (U) schedule W; • B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.
Also known as: ACP-196
Response Based on Overall Response Rate
The best response to treatment was determined according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria incorporating 2012 and 2013 clarifications pertaining to subjects treated with kinase inhibitors. Overall response rate (ORR) was the proportion of subjects who achieved complete response (CR), CR with incomplete marrow recovery (CRi), or partial response (PR) while on treatment before the initiation of new anti-cancer therapy or stem cell transplant.
Time frame: Cycle 1 (28 Days) to 6 months
| Milestone | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive |
|---|---|---|---|---|
| Started | 18 | 14 | 6 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 18 | 14 | 6 | 10 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 12 | 10 | 5 | 6 |
| Withdrew: Discontinued for other reasons | 6 | 3 | 1 | 4 |
The best response to treatment was determined according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria incorporating 2012 and 2013 clarifications pertaining to subjects treated with kinase inhibitors. Overall response rate (ORR) was the proportion of subjects who achieved complete response (CR), CR with incomplete marrow recovery (CRi), or partial response (PR) while on treatment before the initiation of new anti-cancer therapy or stem cell transplant.
| Participants | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Total Relapse/Refractory Subjects | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total Treatment Naive Subjects |
|---|---|---|---|---|---|---|
| Response Based on Overall Response Rate | 17 | 11 | 28 | 6 | 8 | 14 |
Collected over From first dose of study drug until 30 days post last dose for each subject; an average of approximately 38 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib 100 mg BID Relapse/Refractory | 0/18 (0%) | 11/18 (61.1%) | 18/18 (100%) |
| Acalabrutinib 200 mg QD Relapse/Refractory | 1/14 (7.1%) | 8/14 (57.1%) | 14/14 (100%) |
| Acalabrutinib 100 mg BID Treatment Naive | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Acalabrutinib 200 mg QD Treatment Naive | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Event | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/18 | 0/14 | 1/6 | 0/10 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/18 | 0/14 | 1/6 | 0/10 |
| CholecystitisHepatobiliary disorders | 0/18 | 0/14 | 1/6 | 0/10 |
| Pneumonia influenzalInfections and infestations | 0/18 | 0/14 | 1/6 | 0/10 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/18 | 0/14 | 1/6 | 0/10 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/18 | 2/14 | 0/6 | 0/10 |
| PyrexiaGeneral disorders | 2/18 | 0/14 | 0/6 | 0/10 |
| PneumoniaInfections and infestations | 2/18 | 1/14 | 0/6 | 0/10 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/18 | 0/14 | 0/6 | 0/10 |
| EnterocolitisGastrointestinal disorders | 0/18 | 0/14 | 0/6 | 1/10 |
| Event | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive |
|---|---|---|---|---|
| ContusionInjury, poisoning and procedural complications | 11/18 | 9/14 | 6/6 | 6/10 |
| Oedema peripheralGeneral disorders | 3/18 | 4/14 | 5/6 | 2/10 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/18 | 2/14 | 5/6 | 2/10 |
| HeadacheNervous system disorders | 12/18 | 10/14 | 5/6 | 6/10 |
| Influenza like illnessGeneral disorders | 7/18 | 9/14 | 3/6 | 8/10 |
| DiarrhoeaGastrointestinal disorders | 7/18 | 7/14 | 4/6 | 4/10 |
| FatigueGeneral disorders | 4/18 | 5/14 | 4/6 | 3/10 |
| Weight increasedInvestigations | 5/18 | 3/14 | 4/6 | 2/10 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/18 | 8/14 | 1/6 | 5/10 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 5/18 | 8/14 | 1/6 | 4/10 |
| Age, Continuous(Years) | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total |
|---|---|---|---|---|---|
| Mean | 63.3 ± 9.3 | 62.3 ± 7.7 | 68.3 ± 10.9 | 62.1 ± 8.7 | 63.4 ± 8.9 |
| Sex: Female, Male(Participants) | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 2 | 4 | 15 |
| Male | 12 | 11 | 4 | 6 | 33 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 18 | 14 | 6 | 9 | 47 |
| Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 2 | 0 | 2 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 16 | 12 | 4 | 7 | 39 |
| Not Reported | 0 | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Acalabrutinib 100 mg BID Relapse/Refractory | Acalabrutinib 200 mg QD Relapse/Refractory | Acalabrutinib 100 mg BID Treatment Naive | Acalabrutinib 200 mg QD Treatment Naive | Total |
|---|---|---|---|---|---|
| United States | 18 | 14 | 6 | 10 | 48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2015 to primary completion in Jun 2020, 65 months.
Results were first posted in Aug 2021, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 65 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →